Taking Wegovy Every 10 Days Instead of 7: What the Evidence Says

What the pharmacokinetics of semaglutide actually tell us about timing

Semaglutide has a plasma half-life of roughly seven days. That figure is not a coincidence, it is the foundation on which the once-weekly injection schedule was designed. After each injection, the drug concentration in your blood rises, peaks, then slowly falls back over the following week. The next injection arrives just as levels are declining, topping them up and keeping the concentration within the therapeutic window. Do that consistently and you reach a steady state: a stable background level of semaglutide that keeps appetite suppressed and gastric emptying slowed in a predictable way.

Push the interval to 10 days and two things happen. First, the trough concentration (the lowest point before the next dose) falls further than it would on a seven-day cycle. Second, the peak after the next injection may feel more pronounced, because you are injecting into a lower baseline. Neither of these is how the medicine was designed to behave. The NHS patient information for semaglutide is clear that injections should be given on the same day each week, and that if a dose is missed it should be taken within five days, after five days, that dose is skipped entirely and the regular schedule resumed. That five-day window is the outer boundary the medicine's developers considered safe; 10-day spacing goes well beyond it as a routine practice.

None of this means a single delayed injection causes serious harm. Life happens. But treating a 10-day interval as a deliberate strategy is a different matter, and one without any supporting trial data.

What the trial evidence can and cannot tell you about off-schedule dosing

The STEP 1 trial, which underpins Wegovy's UK licence, enrolled adults with obesity or overweight plus a weight-related condition over 68 weeks of once-weekly 2.4 mg semaglutide, producing an average body-weight reduction of around 15 percent. Every participant in that trial dosed weekly. There is no sub-group analysis of what happened to people who dosed every 10 days, because that was not part of the protocol. NICE's recommendation for semaglutide (TA875) likewise assumes the licensed weekly schedule when setting out the conditions under which the medicine represents a reasonable use of NHS resources.

This is worth stating plainly: we do not have good evidence that 10-day dosing produces meaningful weight loss in the long run. We have reasonable pharmacological reasons to expect it would produce less effect than weekly dosing, and no data to suggest it would be safer or better tolerated. The question sometimes arises because people find the first days after an injection the hardest, nausea, fatigue, and digestive discomfort tend to peak around day one or two. Spacing injections further apart might feel easier in the short term. That is understandable. But the solution to tolerability problems is almost never an informal dosing change; it is a conversation with a prescriber about the right titration pace or supportive strategies. If side-effect management is what's behind the question, our page on Wegovy and digestive side effects covers what commonly helps.

What a prescriber would actually consider if you raised this

Prescribers occasionally encounter patients who have, for various reasons, ended up injecting slightly less frequently than weekly, a pen left at a relative's house, a holiday, a short supply gap. The standard clinical response is to return to the regular schedule as soon as possible, not to formalise the extended interval. If supply has been the issue, it is worth knowing that availability of individual doses and pen formats is confirmed at the time of clinical review; a prescriber can advise on how to manage a gap sensibly rather than improvising around it.

If the honest reason behind the question is cost (stretching a pen to reduce monthly spend) it is worth reading about how Wegovy is prescribed and priced through a regulated UK pharmacy before drawing conclusions. Under-dosing to cut costs risks getting neither the safety nor the benefit the medicine is capable of providing. For people weighing up whether the licensed treatment schedule makes sense for them right now, a free consultation with a GPhC-registered prescriber is the right starting point. Our clinical team (introduced at our clinical team page) reviews every case personally, the same day.

There are also people who ask about timing because they are curious whether a longer interval might one day become a licensed option. Longer-acting GLP-1 formulations are in development globally, but as of summer 2026, no extended-interval version of Wegovy is licensed in the UK. The medicine available now is weekly. On that schedule, many people find it helpful to pick a consistent day (say, a Sunday morning before the kettle goes on) and stick to it; the routine itself reduces the chance of a drift that makes the question of interval-stretching feel relevant in the first place.

If you are exploring semaglutide more broadly, our semaglutide overview and Wegovy treatment page cover the full licensed picture, including the newer 7.2 mg dose approved by the MHRA in early 2026. And if you have been wondering about variations in the other direction (shorter intervals) our pages on six-day dosing and fortnightly injections address those questions with the same evidence-led approach.